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KEPENTINGAN PARAS HEMOGLOBIN A2 SEMPADAN DI DALAM POPULASI 
DI KELANTAN 
ABSTRAK 
 
Kira-kira 3-5% daripada rakyat Malaysia adalah pembawa talasemia. Diagnosis talasemia 
yang dibuat bersandarkan kepada parameter hematologi hanyalah sebagai andaian sahaja. 
Analisis DNA diperlukan untuk pengesahan. Hemoglobin A2 (HbA2)  lebih daripada 4.0% 
adalah penanda menunjukkan yang seseorang itu adalah pembawa β-talasemia. Walau 
bagaimanapun, apabila parameter hematologi tidak disokong oleh kenaikan paras 
hemoglobin A2, status mereka sebagai pembawa talasemia sukar dikenalpasti. Kajian 
keratan rentas ini dijalankan untuk menentukan bilangan sampel di HRPZ II yang 
mempunyai paras HbA2 sempadan 3.0% hingga 3.9% dari 1 Januari 2015 sehingga 31 Mei 
2016. 
 
HRPZ II menerima 11,790 sampel untuk pemeriksaan talasemia menggunakan kapilari 
elektroforesis dari seluruh Kelantan. Golongan yang mempunyai HbA2 antara 3.0 dan 3.9% 
telah dipilih dan kemudian profil hematologi mereka (Hb, MCV, MCH, RBC, RDW, 
platelet) dianalisa dan kemudian dipilih secara persampelan rawak untuk menjalani ujian 
molecular bagi mengesan mutasi gen β dan kehilangan gen α. Mutasi pada gen β dikesan 
dengan kaedah molekular MARMS-PCR manakala kehilangan pada gen α dikesan dengan 
kaedah Multiplex Gap PCR.   
 
Daripada 11,790 sampel, seramai 405 (3.4%) didapati mempunyai HbA2 antara 3.0 dan 
3.9%. Seramai 117 (28.9%) sampel dipilih secara persampelan rawak. Daripada 117 sampel, 
45 (38.5%)  menunjukkan keputusan positif ujian molekular sebagai pembawa talasemia di 
mana 36 (30.8%) menunjukkan mutasi pada gen β, 8 (6.8%) menunjukkan kehilangan gen α 
dan 1 sampel (0.9%) menunjukkan kewujudan bersama mutasi pada gen α dan β. Daripada 
xii 
 
37 sampel dengan mutasi pada gen β, 32 (86.5%) mempunyai satu mutasi gen manakala 5 
(13.5%) dengan dua mutasi gen. 
 
Mutasi gen β paling kerap dikesan ialah CD 19 (A-G) (45.9%), diikuti oleh IVS 1-1 (G-A) 
(24.3%), Poly A (13.5%) dan CAP 1 (A-C) (2.7%). Terdapat perkaitan yang signifikan 
antara tahap HbA2 yang berbeza dan hasil ujian molekular. Seramai 10 orang (27.0%) 
menunjukkan keputusan positif mutasi gen β walaupun HbA2 hanya 3.0%. 
 
Daripada kajian ini, terdapat sebilangan golongan yang mempunyai HbA2 3.0% hingga 
3.9% dikesan sebagai pembawa talasemia dari ujian PCR. Kajian ini diharap dapat 
membuka ruang untuk penilitian semula tahap HbA2 untuk menjayakan pengesanan 
program β-talasemia. 
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THE SIGNIFICANCE OF BORDERLINE HAEMOGLOBIN A2 LEVEL AMONG 
KELANTAN POPULATION 
ABSTRACT 
About 3-5% of Malaysians are thalassaemia carriers. Thalassaemia diagnosis based on 
haematological parameters is presumptive thus DNA analysis becomes necessary. 
Haemoglobin A2 (HbA2) level higher than 4.0% is a classic marker of β-thalassaemia 
carriers. However, when haematological parameters are suggestive of thalassaemia 
phenotype but not supported by HbA2 increment, this finding may put the diagnosis into 
dilemma. This cross sectional study was conducted to determine the proportion of borderline 
HbA2 level among samples taken for haemoglobin (Hb) analysis in HRPZ II from January 
2015 until March 2016. 
 
HRPZ II received total of 11,790 samples for thalassaemia screening by CE from all over 
the state. Samples with HbA2 between 3.0% and 3.9% were selected and their 
haematological profiles (Hb, MCV, MCH, RBC, RDW and platelets) were analysed and 
then randomly selected for molecular testing (PCR) for β-gene mutation and α-gene 
deletion. MARMS-PCR was used for β-globin gene mutation detection while α-globin genes 
deletion detected by Multiplex Gap-PCR method. 
 
From 11,790 samples, 405 (3.4%) samples were found to have HbA2 between 3.0 and 3.9%. 
Out of that, 117 (28.9%) samples were selected by simple random sampling to proceed with 
PCR. From 117 samples, 45 (38.5%) showed positive molecular result in which 36 (30.8%) 
showed β-globin gene mutations, 8 (6.8%) showed α-globin gene deletions and 1 sample 
(0.9%) showed coexistence of α- and β-globin gene mutations. Out of these 37 samples with 
β-globin gene mutations, 32 (86.5%) had single gene defect while 5 (13.5%) had two gene 
mutations.  
xiv 
 
The commonest of single β-gene mutation detected were Cd 19 (A-G) (45.9%), followed by 
IVS 1-1 (G-A) (24.3%), Poly A (13.5%) and CAP +1 (A-C) (2.7%). There was statistically 
significant association between HbA2 levels and positive molecular result. Interestingly, this 
study also showed 10 (27.0%) positive β-gene mutation even though the HbA2 level was 
normal at only 3.0%. 
 
There was significant number of people with borderline HbA2 and confirmed as 
thalassaemia carriers by PCR. This study revealed an important finding to consider revision 
of HbA2 range and haematological parameters that should prompt for DNA analysis in case 
of borderline HbA2 for the success of thalassaemia screening programme in our population. 
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1.0 INTRODUCTION 
 
The thalassaemia is a heterogeneous group of genetic disorders with defective synthesis of 
one or more globin chains. It was originally confined to the tropics and subtropics region 
with high incidence rates. Beta thalassaemia (β-thalassaemia) is commonly found in 
Mediterranean basin, Middle East and Asia while alpha thalassaemia (α-thalassaemia) 
predominates in South East Asia. However due to the increasing global migration, this 
haemoglobin (Hb) disorder can also be seen in the areas where they were not originally 
endemic (Ministry Of Health Malaysia, 2016). 
 
In Thailand and other Southeast Asian countries, thalassaemia is very common with 20–30% 
of the population having the α-thalassaemia trait, 3–9% having β-thalassaemia trait whereas 
20–30% having the HbE trait (Srivorakun et al., 2011). In Malaysia, thalassaemia is one of 
the common genetic abnormalities with 4.5% of Malaysians are carriers of β- thalassaemia 
(George, 2001). 
 
Until November 2015, according to the thalassaemia registry, total number of transfusion 
dependent thalassaemia (TDT) patients in Malaysia was 6646. Sabah presented with the 
highest TDT cases which is more than 1600 patients while Kelantan, the place where this 
study was conducted has more than 250 TDT patients (Ministry Of Health Malaysia, 2016). 
 
Thalassaemia gives financial burden to this country. It was estimated that RM 3 million 
needed for treatment of thalassaemia major patient until they reach 30 years old. Therefore, 
prevention of this disease is more cost effective. Developing a prevention programme is 
important in reducing the birth of blood transfusion dependent thalassaemia considering the 
3 
 
cost needed for the optimal care of affected patients and also socio economic burden to 
patients, family members and government (Ministry Of Health Malaysia, 2016). 
 
The thalassaemia and haemoglobinopathy screening is based on the detection of red cell 
indices, Haemoglobin A2 (HbA2) value, Haemoglobin F (HbF) and Hb variant values. Even 
though diagnosis of β-thalassaemia can be made base on haematological parameters, the 
diagnosis is only presumptive. Thus in these cases, molecular test by Polymerase Chain 
Reaction (PCR) becomes necessary (Giambona et al., 2009).  
 
HbA2 determination plays an important role in the screening programs for β-thalassaemia in 
which if the value is more than 4.0% with normal HbA and HbF, the person will be 
diagnosed as β-thalassaemia carrier. Individuals with “grey zone” or  borderline HbA2 are 
difficult to be classified base on haematological parameters alone (Giambona et al., 2008). 
The individuals who have borderline HbA2 values are not rare, ranging from 2.2% to 16.7% 
among population in the countries where thalassaemia is commonly seen (Lou et al., 2014). 
If PCR test was not done among borderline HbA2 samples, significant numbers of 
thalassaemia carriers will be missed with probability of birth of an affected offspring. 
Various factors can contribute for normalization of HbA2 that can interfere with carrier 
detection such as mild β-thalassaemia mutations and coinheritance of other molecular defect 
such as α- or δ-thalassaemia (Colaco et al., 2012). 
 
Borderline HbA2 level in this study was justified at the level between 3.0% - 3.9% even 
though few previous studies done had classified borderline HbA2 level between  3.3% to 
3.7% (Mosca et al., 2008; Lou et al., 2014) and 3.1% to 3.9% (Giambona et al.,2008; 
Sharma et al.,2015). While previous researchers used High Performance Liquid 
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Chromatography (HPLC) to quantify HbA2, this study used capillary electrophoresis (CE) 
method. Thus, HbA2 level between 3.0% and 3.9% were taken as borderline values in this 
study as HbA2 level by CE was significantly lower than HPLC (Alauddin Hafiza MBBS et 
al., 2012; Borbely et al., 2013).  
 
The aim of this study was to determine the proportion of borderline HbA2 value and its 
significance in diagnosing β-thalassaemia among Kelantan populations. Samples with 
borderline HbA2 were randomly selected for molecular test with Multiplex Amplification 
Refractory System (MARMS) PCR for β-thalassaemia detection and Multiplex Gap-PCR for 
α-thalassaemia gene deletion. The haematological profiles will be studied together with the 
spectrum of thalassaemia mutations. To perform molecular test to all samples with 
borderline HbA2 is not permissible due to logistic reason and financial constraint. But 
neglecting and labelling the samples as normal might cause at risk couple to give birth to an 
affected offspring, which can give rise to bigger nuisance for the nation. In addition, false 
assurance from the test results may have legal implications. 
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2.0 LITERATURE REVIEW 
 
2.1 The haemoglobin 
Each red blood cell (RBC) contains approximately 300 million molecules of Hb. Hb consists 
of haem and globin components. Haem is vital to transport oxygen to the tissues while 
globin will protect haem from oxidation, provide the solubility to the molecule and gives 
variation to the oxygen affinity. Two pairs of globin chains formed one molecule of Hb, 
each of which encompasses an iron containing porphyrin designated haem. These highly 
specialised molecules act as oxygen transporter from the lungs to the tissues (Bain, 2006). 
 
From the time of fertilization until adulthood period, there are four major types of Hb which 
started with ‘embryogenic Hb’, represent ζ2ε2 (Hb Gower 1), α2ε2 (Hb Gower 2), ζ2γ2 (Hb 
Portland 1) and ζ2β2 (Hb Portland 2). These kinds of Hb are detected during 3rd to the 10th 
week of gestation. Towards foetal period, the predominant oxygen carrier is ‘foetal’ Hb or 
HbF that consist of α2γ2 molecule. Shortly after birth, adult Hb (HbA) that consists of α2β2 
molecule will replace HbF.  
 
There are also other trait adult Hb components that consist of α2δ2 which are HbA2. Under 
normal condition, the red cells of an adult human contain approximately 97-98% of HbA, 2-
3% of HbA2 and traces of HbF (Federation, 2014). Figure 2.1 illustrates different types of 
Hb from embryonic period until first year of life.  
 
 
7 
 
 
Figure 2.1: Different expression of human globin chain in different stages of life (adapted 
from (A. Victor Hoffbrand, 2016)). 
 
Each of α- and β-like globin chains are encoded by genetically different loci. The α-like 
cluster is located on the tip of short arm of chromosome 16 while β-like cluster is located on 
chromosome 11p15.5. The β-genomic sequence codes for 146 amino acids, has three exons 
(coding regions) that interrupted with two introns. Intron 1 interrupts the sequence between 
codons 30 and 31 while intron 2 between codons 104 and 105. The α-globin genes which 
encode for 141 amino acids have introns between codons 30 and 31 and also 99 and 100.  
 
The appropriate genes of α- and β-gene clusters are expressed accordingly to maintain the 
normal production of α-and β-like globin chains to produce normal Hb level and type. The 
regulation of globin gene expression is mediated at several levels. Most will be regulated 
during transcriptional level, but with some adjustment during and after translation level (A. 
Victor Hoffbrand, 2016). Figure 2.2 showed the genomic structure of α-like and β-like 
globin clusters on chromosome 16 and chromosome 11. 
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Figure 2.2: Genomic structure of α-like and β-like globin clusters (adapted from (A. Victor 
Hoffbrand, 2016)). 
 
2.2 Global epidemiology and population genetics of thalassaemia 
Cooley and Lee in 1925 first described a form of severe anaemia that occurred early in life 
with presence of splenomegaly and skeletal changes. George H. Whipple and William L. 
Bradford had published a comprehensive pathologic finding of this disease in 1932 with the 
phrase or ‘thalassic’ (sea) anaemia due to Mediterranean background of early patients. The 
phrases were later became thalassaemia (Marshall A. Litchman, 2006).  
 
Thalassaemia were originally endemic in 60% of 229 countries, potentially affects 75% of 
births. Around 1.1% of couples worldwide are at risk for having children with a Hb disorder 
and 2.7 per 1000 conceptions are affected (Modell and Darlison, 2008). There are 4.5% (270 
million) thalassaemia carriers worldwide with 60,000 thalassaemia major patients are born 
every year (Ministry Of Health Malaysia, 2016). 
 
In many parts of the world, thalassaemia contributes to major health problem. The 
thalassaemia syndromes are a group of inherited disorders manifested with anaemia. During 
those days when thalassaemia was discovered, these conditions were frequently encountered 
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among people from the Italian, Greek coasts and nearby islands. The prevalence of 
thalassaemia in the regions known as ‘thalassaemia belt’ was around 2.5 to 15%. 
Thalassaemia belt’ extends along the shores of the Mediterranean and throughout the 
Arabian Peninsula, Turkey, Iran, India and South East Asia (Ronald Hoffman, 2013) .  
 
Five to ten percent of the population in South Italy and Greece were heterozygous for β-
thalassaemia whereas in Thailand, the gene frequency for the various forms of thalassaemia 
was approximately around 25% (Gary Moore, 2010). Thalassaemia is commonly seen in 
countries with high population of immigrants (Marshall A. Litchman, 2006). The Asian, 
Indian, and Middle Eastern regions account for 95% of thalassaemia births worldwide. The 
rapid growth in the thalassaemia population from these regions has changed the clinical 
picture of thalassaemia worldwide. Today’s epidemiology of thalassaemia is strikingly 
different from that of the past involving ethnicities, phenotypes, and treatments (Vichinsky, 
2005). 
 
This disorder is characterized by quantitative defects in the synthesis of one or more of 
globin chain subunits of the Hb tetramer. The individual thalassaemia syndromes are named 
according to the globin chain whose synthesis is adversely affected, either reduced or absent 
production of one or more globin chains (Ronald Hoffman, 2013) .  The quantitative defect 
of the globin chain results in serious abnormality in the Hb molecule, which leads to poor 
oxygen transport. Patient will subsequently manifest with sign and symptoms of anaemia 
and ineffective erythropoiesis (Gary Moore, 2010). In each of the high frequency areas for 
the β-thalassaemia, a few common mutations and varying numbers of rare mutations are 
seen. The mutation pattern is different in each of these regions (Marshall A. Litchman, 
2006). 
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Anaemia is the common characteristic of thalassaemia but this hereditary Hb disorder has 
wide spectrum of clinical severity. Clinically, thalassaemia becomes a significant disorder 
when the patient has severe anaemia that needs regular transfusion. These include β-
thalassaemia major/intermedia, compound HbE/β- thalassaemia and some types of non-
deletional α-thalassaemia (Old et al., 2013). 
 
The thalassaemia syndromes especially the transfusion dependent type are serious burden to 
the health services worldwide, not only because of requirement of multiple blood 
transfusions for thalassaemia major patients but also includes the milder type of 
thalassaemia, known as thalassaemia intermedia or non-transfusion dependent thalassaemia. 
This type of thalassaemia requires thorough and serial monitoring since complication may 
expect to arise at any time. The need for lifelong monitoring with the manifestation of 
complications affecting major organs such as endocrine glands, heart and liver creates the 
necessity to organise expert services and also the need for major resources in managing 
essential drugs and donated blood for transfusions. By implementing the holistic approach, 
thalassaemia patients are expected to survive without compromising their quality of life (Old 
et al., 2013). 
 
2.3 Thalassaemia screening in Malaysia 
Ministry of Health Malaysia has estimated that 350 of β-thalassaemia major and 120 of Hb 
Bart hydrops fetalis patients were delivered every year in this country. This number was 
calculated by Hardy-Weinberg equation (Ministry Of Health Malaysia, 2016). Hardy-
Weinberg equation is a simple mathematical expression formulated by mathematics 
professor from Cambridge University, Godfrey Harold Hardy and a physician from 
Stuttgart, Germany, Wilhelm Weinberg in 1908. This equation relates allele with genotype 
frequencies in a population, predicted the stability of their relationship from one generation 
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to the next with the assumption that allele and genotype frequencies do not change over the 
cause of many generations (Shukla, 2009). 
 
Survival rate of thalassaemia major patients depend on the socioeconomic status. Those born 
in high-income countries survive with a chronic disorder while children who born in low-
income countries mostly die before the age of 5 years old (Modell and Darlison, 2008). 
Thalassaemia is a burden to this country in terms of financial allocation and its effect to the 
productivity of the country. It was estimated that RM 3 million needed for treatment of 
thalassaemia major patient until they reach 30 years old. Therefore, prevention of this 
disease is more cost effective (Ministry Of Health Malaysia, 2016). The estimated costs 
needed for treatment of a thalassaemia patient are listed in Table 2.1. 
 
Table 2.1: The cost for treatment of a thalassaemia patient 
Treatment description Estimated cost 
 
Blood test every 6 months RM 500 
1 blood filter RM70 
1 unit of packed cells RM 200 
1 desferal infusion pump RM 2500 
1 Thalaset needle RM 10 
MRI T2 RM 1200 
Adapted from (Ministry Of Health Malaysia, 2016) 
 
Iron chelation therapy is mandatory for every transfusion dependent thalassaemia patient to 
avoid complication of iron overload. It is a major contribution of the high cost for treatment 
of thalassaemia patient. The algorithms for iron chelation in transfusion dependent 
thalassaemia are described in Figure 2.3. 
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Figure 2.3: The algorithms for iron chelation in transfusion dependent thalassaemia 
(adapted from (Ministry of Health Malaysia, November 2009)). 
 
The algorithm shows that iron chelation therapy usually started as early as 2 years of age, 
with the frequency of 5 nights per week. Owing to the necessity of iron chelators, the costs 
of these medications are listed in Table 2.2. 
Table 2.2: The costs of iron chelating agents 
Iron Chelators Cost 
 
Deferiprone (tablet) 9tablets/day   RM 29 
Deferiprone (syrup) 45mls/day RM 54 
Desferrioxamine 2g/ day RM 43 
Deferiserox (Exjade) 1.5g/day RM 274 
Adapted from (Ministry Of Health Malaysia, 2016) 
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Multi organ toxicity due to iron overload that often observed as a complication in 
transfusion dependent thalassaemia patients were growth impairment, pubertal delay, cardiac 
and lung dysfunction and hypothyroidism. 
 
By listing the cost needed to treat one thalassaemia patient, one will clearly realize how 
important for Malaysian government to start the thalassaemia screening programme in the 
country in which 1 in 10 of their people carry these thalassaemia genes. Early prevention is 
recommended as it could be beneficial to the person with a family history of this Hb disorder 
as the mode of inheritance is autosomal recessive. Since the late 1970s, genetic counselling 
and prenatal diagnosis have been introduced among the population at risk in the 
Mediterranean region where thalassaemia is endemic. The screening programs had been very 
effective since an intensive education were given to couples to make a correct decision 
before conceive (Rashid et al., 2012).   
 
Hence on 25th of August 2004, Malaysia cabinet has endorsed national programme in 
Malaysia designated as ‘Thalassaemia Prevention and Control Programme’ which had listed 
4 major components: 
1. Public awareness and health education  
2. Comprehensive management of patients 
3. Population screening and laboratory diagnosis 
4. Thalassaemia registry 
 
Without this screening programme, the birth rate of affected offspring will be more or less 
remains the same. The targeted group for thalassaemia screening were Form 4 students, 
volunteers, family and cascade screening (Ministry of Health Malaysia 2016). Selection of a 
test for population wide screening programmes involves a practical approach, weighing the 
14 
 
test specificity and sensitivity that is not only economical but also easy to handle. In country 
such as Malaysia who involves in screening programme for thalassaemia, initial screening 
with haematological indices is needed in order to select samples with some criteria that need 
to proceed with Hb analysis and if needed, with confirmatory PCR test. Thus, it is essential 
for the screening to have high specificity with high negative predictive vales to ensure that 
the programme does not miss thalassaemia carriers (Nadarajan et al., 2010).  
 
While family and cascade screening will usually suggested by clinicians or 
haematopathologist upon reviewing Hb analysis result that possibly a thalassaemia carrier, 
screening for form 4 students had encountered difficulties to pursue. The pioneer project was 
started in 2005-2006 in Penang, Sabah and Malacca. Pioneer project in Penang which 
involved 7,281 form 4 students from 37 schools however had gained only 42% written 
consent from parents on first attempt and 59% on second attempt owing to lack of 
promotions (Ministry of Health Malaysia 2016).  
  
Bahagian Pembangunan Kesihatan Keluarga on 22nd of May 2015 had presented a proposal 
to Deputy Health Minister I for thalassaemia screening among form 4 students. Hence from 
2016, the screening programme for form 4 students has been started with aim for 95% 
reduction of affected off springs by year of 2038 (Ministry of Health Malaysia 2016).  
 
Hospital Raja Perempuan Zainab II as one of the centre for thalassaemia screening 
programme in Malaysia which received all Hb analysis samples in Kelantan state was also 
involved in this project. Ministry of Health had designed an algorithm for voluntary and 
cascade screening as shown in Figure 2.4. 
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The objectives of screening programme for thalassaemia in Malaysia were to detect β-
thalassaemia carrier and to reduce the likelihood of birth of affected offspring from 
marriage of thalassaemia carrier parents. Screening is usually done base on haematological 
parameters including red cell indices and Hb variant values. HbA2 determination plays a 
key role in making diagnosis of β-thalassaemia in which HbA2 level more than 4.0% is a 
classic marker of β-thalassaemia carriers (Mosca et al., 2009). 
 
To achieve the objective of this screening programme, starting from 2008, 192 of 
government health clinics were equipped with haematological analyser while main 
hospitals were provided with HPLC machine. The numbers of haematological analysers 
available in health clinic were increased to more than 400 machines in 2012 (Ministry Of 
Health Malaysia, 2016).  
 
2.4 The β-thalassaemia 
The inherited disorder of Hb, the thalassaemia and the structural Hb variant were the first 
human single defective gene disorder to be studied in a systematic manner at molecular level 
with great discovery about their phenotype-genotype relationship (Gribben, 2010). Β-
thalassaemia is prevalent in Mediterranean countries, the Middle East, Central Asia, India 
Southern China and the Far East as well as countries along the north coast of Africa and in 
South America. The highest carrier frequency is reported in Cyprus (14%) followed by 
Sardinia (10.3%) and Southeast Asia. The high gene frequency of β-thalassaemia in the 
region mentioned is most likely related to the selective pressure from Plasmodium 
falciparum infection (Flint et al., 1998). 
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Thalassaemia and haemoglobinopathy are the commonest single gene disorders known. This 
syndrome is so common in some regions that the majority of the population carries at least 
one genetic abnormality that may affect Hb structure. The prevalence of this disease is 
attributed with the protection against malaria. The distributions of malaria and common 
haemoglobinopathies largely overlap and the relationship between thalassaemia or 
haemoglobinopathy with protection against Plasmodium falciparum infection have been 
confirmed by microepidimiological surveys. However, it is later found that in some areas, 
malaria and haemoglobinopathies are not coincidentally happened together which might be 
as a result of sporadic mutations in local populations (Flint et al., 1998).  
 
The β-thalassaemias are a group of conditions resulting from reduced rate of synthesis of β-
globin. It is extremely heterogeneous at the molecular level. More than 200 different 
mutations present on chromosome 11 have been found in association with the β-
thalassaemia phenotype which result in reduced or absent synthesis of β-globin chains. 
These mutations maybe located within the gene complex or on nearby promoter or enhancer 
region (Gary Moore, 2010). The majority of these mutations are single nucleotide 
substitutions, deletions, or insertion of nucleotides and leading to frame shift mutation. 
Clinical severity of β- thalassaemia is related to the extent of imbalance between α- and non 
α-globin chains (Srisupundit et al., 2013). 
 
Several β-thalassaemia mutations are responsible for the majority of β-thalassaemia among 
Malays and Chinese in Malaysia. Among Malaysian Chinese, there are five common β-
globin mutations: Cd 41/42 (–TTCT), IVS2-654 (C-T), –28 (A-G), Cd 17 (A-T) and Cd 
71/72 (+A) (Mary Anne Tan et al., 2006). Among Malays in this country, the common 
mutations seen are codon 26 (HbE), IVS 1-1 and IVS 1-5 (George et al., 1992).  
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Considered as autosomal recessive inheritance, molecular analysis of β-thalassaemia 
demonstrated a notable heterogeneity. Each of the populations in high prevalence area has 
own unique group of mutations owing to the local selection due to malaria. The large 
majority of β-thalassaemia mutations are point mutations which can involve any step in 
globin chain production either transcription, translation or post translational stability of the 
globin gene product (A. Victor Hoffbrand, 2016).  
 
2.4.1 Characteristic of β-thalassaemia 
β-thalassaemia major patient usually presented at 6 months to two years of life with failure 
to thrive, feeding problems, diarrhoea, irritability, progressive pallor, progressive abdominal 
distension and recurrent fever. Thalassaemia major patient is usually transfusion dependent. 
The sign and symptoms of thalassaemia in developing countries due to in adequate blood 
transfusion are growth retardation, pallor, jaundice, genu valgus, leg ulcers, 
hepatosplenomegaly and skeletal changes (Galanello and Origa, 2010). Thalassaemia 
intermedia sometimes will present later at life and may or may not require blood transfusion 
depending on the severity. Thalassaemia trait is clinically asymptomatic but sometimes 
presented with mild degree of anaemia. As thalassaemia is an autosomal recessive disorder, 
there is 25% risk at each pregnancy of having children with thalassaemia major if both 
parents are thalassaemia carriers (Galanello and Origa, 2010). 
 
 
2.4.2 Pathophysiology of β-thalassaemia 
Molecular defect in β-thalassaemia leads to reduce or absent β-chain production. Imbalance 
in globin chain production results in a relative excess of unbound α-globin chains that 
precipitate in erythroid precursors in the bone marrow forming intracellular inclusions. The 
degree of globin chain imbalance is determined by the nature of the mutation in short arm of 
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chromosome 11 where β-globin chain is located. When excess α-globin chain degraded, the 
end product particularly haem and iron produce harmful effect on red cell membrane 
proteins and lipids that caused red cells become less deformable and has shortened survival. 
Destruction of the erythroid precursor is called as ineffective erythropoiesis (A. Victor 
Hoffbrand, 2016).  
 
 
Insoluble α-globin chain induce membrane damage to the peripheral RBCs that result in 
peripheral haemolysis and leads to anaemia. Hence, anaemia in β-thalassaemia results from 
ineffective erythropoiesis and haemolysis. Prolonged and severe anaemia is compensated by 
extramedullary erythropoiesis and results in hepatosplenomegaly. β-thalassaemia stimulates 
erythropoietin production that results in bone marrow expansion and may lead to serious 
deformities of skull and long bones. Some adult red cell precursors that produce variable 
amount of gamma (γ) chains can combine with excess α-chains to form HbF that provide 
protection against deleterious effect of α-chain precipitation (A. Victor Hoffbrand, 2016). 
 
 
In transfusion dependent thalassaemia, steady accumulation of iron in the liver, endocrine 
glands and myocardium might occur as each unit of blood contains 200-250mg of iron. 
Thus, TDT patient may die following complication of iron overload. Figure 2.5 showed 
pathophysiology of β-thalassaemia (A. Victor Hoffbrand, 2016). 
 
20 
 
 
 Figure 2.5: The pathophysiology of β-thalassaemia (adapted from (A. Victor Hoffbrand, 
2016)). 
 
2.4.3 Molecular genetics of β-thalassaemia 
The β-globin gene is located in the short arm of chromosome 11. Besides β-globin chain, δ-
globin gene, embryonic ζ-gene, fetal A-γ and G-γ genes and pseudogenes ψB1 also share the 
same region. 1.6kb haemoglobin subunit beta (HBB) gene containing three exons and both 
5’ and 3’ untranslated regions (UTR) is regulated by an adjacent 5 promoter in which 
TATA, CAAT and duplicated CACCC boxes are situated. 50kb from β-globin chain is a 
major regulatory region that contains strong enhancer. This region known as locus control 
region (LCR) contains four (HS-1, HS-2, HS-3 and HS-4) erythroid specific DNAse 
hypersensitive sites (HSs) which act as hallmark of DNA-protein interaction (Cao and 
Galanello, 2010). 
 
Combination of several DNA motifs interacting with transcription factors to constitute each 
HS site. The most important one are GATA-1, nuclear factor erythroid 2, eryhroid Kruppel-
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like factor and friend of GATA 1. The significance of this LCR is to control β-like globin 
gene expression has been studied in which if HS sites are totally or partially remove, it will 
result in the inactivation of β-globin gene. The arrangements of these genes are shown in 
Figure 2.6. 
 
 
 
 
Figure 2.6: Location of the chromosomes with the structure of α and β gene clusters 
(adapted from (Cao and Galanello, 2010)). 
 
From more than 200 disease-causing mutations of β-thalassaemia that have been identified, 
majority of the mutations are single nucleotide substitutions or deletions, or insertions of 
oligonucleotides leading to frameshift (Cao and Galanello, 2010).  
 
There are three different categories of point mutations affecting the β-globin expressions 
which consist of: 
1) Promoter and 5’ UTR mutations that lead to defective β-gene transcription 
2) Mutations affecting mRNA processing which includes splice junction and consensus 
sequence mutations, polyadenylation, and other untranslated regions mutation.  
3) Mutations resulting in abnormal mRNA translation that consist of initiation codon 
mutations, nonsense and frameshift (Cao and Galanello, 2010). 
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Study done by Saripah et al. among transfusion dependent thalassaemia patient in Kelantan 
showed that Cd 26 (G>A) HbE was the commonest (84.78%) β chain mutation defect 
detected by MARMS PCR method (Hanafi et al., 2014). Another study done among β-
thalassaemia carrier and patients in Malaysia showed high frequency of carriers with Cd 26 
(G–A), IVS1–5 (G–C), IVS 1–1 (G–T), and Cd 41/42 (–TTCT) among the Malays (Hassan 
et al., 2013). 
 
β° is characterized by complete absence of β chain production as a consequence of deletion, 
initiation codon, nonsense, frameshift, and splicing mutations. β+ is characterized by reduced 
production of β chain production as a result of mutations in the promoter area (either the 
CACCC or TATA box), the polyadenylation signal, and the 5_ or 3_ UTR or by splicing 
abnormalities (Cao and Galanello, 2010). 
 
β+ mutation is further characterized into severe, mild and silent base on reduction of β-globin 
chain. The silent mutations have normal haematological findings and defined only by a 
mildly imbalanced alpha/beta globin chain synthesis ratio. Silent mutations result from 
mutations of the distal CACCC box, the 5_ UTR, the polyadenylation signal and some 
splicing defects. The mild mutations show moderate thalassaemia-like haematological 
features and imbalanced globin chain synthesis and are produced by mutations in the 
proximal CACCC box, TATA box, 5_ UTR, or exon 1, causing alternative splicing (Hb 
Malay, HbE, and codon 24 T3A), or in the consensus splicing sequence, 3_ UTR, and poly-
A site (Cao and Galanello, 2010).  
 
Mutations activating a cryptic splicing site in exon 1, at codons 19, 26, and 27, are 
associated with a mild or silent phenotype, and result in the production of the abnormal Hb 
Malay, HbE and Hb Knossos. A few β0-thalassaemias display a mild phenotype such as 
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Cd6-A and Cd 8-AA (Cao and Galanello, 2010). List of mild and silent HBB gene mutations 
are shown in Table 2.3. 
 
Table 2.3: Mild and silent HBB gene mutations causing β- thalassaemia.  
Mutation type or location Mild β+ Silent 
Transcriptional mutants in 
the proximal CACC box 
-90 C>T 
-88 C>T 
-88 C>A 
-87 C>T 
-87 C>G 
-87 C>A 
-86 C>T 
-86 C>T 
 
-101 C>T 
-92  C>T 
TATA box -31 A>G 
-30 T>A 
-29 A>G 
 
 
5’ UTR +22 G>A 
+10 -T 
+33 C>G 
 
 
 
+1’ A>C 
Alternative splicing Cd 19 A>C 
(Hb Malay) 
Cd 24 T>A 
 
Cd27 G>T 
(Hb Knossos) 
Consensus splicing IVS 1-6 T>C 
 
 
Intron   IVS2-844 C>G 
 
3’ UTR  +6 C>G 
 
Poly-A site AACAAA 
AATGAA 
 
AATAAG 
Mild β° frameshift Cd 6-AA 
Cd 8-AA 
 
 
(Adapted from (Cao and Galanello, 2010) 
 
The presumptive diagnostic feature of heterozygous β-thalassaemia is the hypochromic 
microcytic RBC with increased HbA2 level. Normal HbA2 β-thalassaemia refers to the forms 
in which the blood picture is characteristic of heterozygous β-thalassaemia except for the 
fact that HbA2 is normal (Cao and Galanello, 2010). 
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2.5 The alpha thalassaemia (α-thalassaemia) 
In view of high prevalence of α-thalassaemia in Southeast Asia region, co-inheritance of α 
with β-thalassaemia was postulated to be one of the causes of normal or borderline HbA2 
level (Saleh-Gohari et al., 2015). Thus, the molecular test for α-thalassaemia by Multiplex 
Gap-PCR method was done. 
 
The molecular pathology of the α-thalassaemia is more complicated than β-thalassaemia in 
view of presence of two globin genes per haploid genomes (Gribben, 2010). The α-
thalassaemia is characterized by the decrease or complete suppression of α-globin 
polypeptide chains, resulting from over 128 different deletions or point mutations of the α-
globin genes. The α-globin genes are located at the short arm of chromosome 16 (16p13.3). 
In normal individual, there are four functional α-genes, genotyped as αα/αα (Harteveld and 
Higgs, 2010). 
 
Malaysia and its neighbouring Southeast Asian countries have a high prevalence of α-
thalassaemia. The carrier rate for α-thalassaemia of the South East Asian type among 
Malaysian Chinese was around 4.5% (Rahimah et al., 2012). α-thalassaemia is an inherited 
autosomal recessive disorder caused by a complete absence or reduces production of α- 
globin peptides due to a deletion or mutation of one or more of the four α-globin gene (two 
on each copy of chromosome 16). Deletion of one or both α-globin genes are the commonest 
form of α thalassaemia. Rarer non deletional α-thalassaemia resulting from point mutations 
is commoner in Southeast Asia region than any other part of the world (Harteveld and 
Higgs, 2010). In order to determine genotypes of the thalassaemia carrier, the accurate 
determination of the carrier phenotype is necessary. This can be done through 
haematological indices in full blood count (FBC).  
